Member Info for WBAFC

Gizmo , is this what you are talking about.

https://www.fiercebiotech.com/medtech/pacbio-plots-budget-cuts-after-dna-sequencing-revenue-shortfalls

Looking at the turnover over of Pacbio , it gives me great encouragement that Yourgene can bring in huge revenues and create shareholder value.

Lets recap with the RNS made on 16th June 2022 by Novacyt

On 15 June 2022, the Company filed a defence of the claim received on 25 April 2022 and a counterclaim of £81.5m against the DHSC. The value of the counterclaim is broadly in line with the amounts previously announced by the Company in its full year 2020 results, plus related interest. The Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including recovering outstanding sums due from the DHSC under the counterclaim.'

Can this statement be taken also to mean also reputational damages and loss of earnings incurred ?

https://www.lse.co.uk/rns/NCYT/dhsc-dispute-update-ldcfhiyo5p85qx6.html

Flatlander , good question . I actually asked this question few months ago but no one replied . I pointed out that Novacyt should be compensated for reputational damage as it would have affected their business considerably .

Kaeren , Novacyt is not just a viral diagnostic testing company, but now is largely a reproductive genetic diagnostic testing company . So we don't need to be in a pandemic situation.

Why would there be a sudden surge in buying at close i wonder ? Just imagine a cash rich Novacyt with £130M+ in the bank . This would transform the company with the right acquisitions. I remember Biosynex reached €26 / share at its peak , so what stopping Novacyt reaching those heights after a favourable DHSC result.

60K buy on French stock market

Maybe director buys or positive RNS this week ?

According to this gizmo555 , the test you have mentioned is 99% accurate

https://www.dynacare.ca/patients-and-individuals/health-solutions/prenatal-solutions/harmony-nipt.aspx#:~:text=The%20Harmony%20test%20from%20Dynacare%20Prenatal%20Solutions%20detects%20T21%20(Down,accuracy%20rate%20greater%20than%2099%25.&text=Preparation%20Instructions%3A%20none.

Now that Novacyt have a new CEO and executive director , will we therefore expect a new LTIP next Month ? Or possibly the CEO and CSO buying some shares up. I think, the fact that they have no inside information of how the court case will go , may allow them to be in the buying period.

HarChris , exactly why I think there must be a big contract on its way. Why would a ruthless chairman, JW , want to employ a CEO that basically bankrupted his company. LR must have presented a business strategy to JW , to convince him plans for Yourgene. And it must be very lucrative.

I don't think LR would need much time for acquisitions or times needed as a CEO . He has been CEO at Yourgene since 2018 and will know what aquisitions are required, and business strategy for Yourgene already in place. Novacyt now is basically Yourgene with a little Primerdesign business. I expect some big contracts coming to Yourgene soon. This is why LR is in place as CEO.

My thinking is JW would not have appointed LR as CEO if there wasn't something going to happen. I mean through Yourgene business there must be a big contract on its way . And LR is being rewarded. Do you think James McCarthy would have been happy ? No way , but he would have no choice but to move to one side if Yourgene was bringing in a big contract win. I think this contract will be declared after the DHSC dispute has been delt with.

So DHSC win £130M + £ big contract for Yourgene = Cash rich Novacyt

Hi Handy111 , thanks for the message. Yes , I have invested huge amounts in Novacyt , just hope, and pray we have the right people in charge now , who have good intentions to want to protect shareholder value , as well as building the company up, and can look back on their lives , and be proud of. This could be an massive opportunity for LR , Joanne Mason , and James Wakefield to put their mark on this company and develop it into a mid cap organisation. With the potential money from DHSC case , they have certainly got the potential. All we want is that shareholders who have invested and have high averages are protected , because we were sold on the basis that this company was going to be mid cap and a leading international diagnostic company.

CaptainSwag , are we correct to say that James Wakefield has been dictating business strategy at Novacyt ? I think for sure , he has been wipping BOD , as evidenced by DA being booted out , JM removed from CFO and now out of CEO and Novacyt . Will JW be able to control or indeed want to dictate this new CEO appointed ? How much power will LR have in reality ? Is LR going to take this Novacyt by the horns and give it a good blast to grow this company . Or is he just going to pass the time and take his comfortable salary .

I am really really keen to know what LR's vision is with this company now . Not only that , but i want to know how he plans to do it , his strategy ?

So the fact we have had David Allmond who was pushed out from CEO and James McCarthy who was moved out of his CFO job suggests to me that James Wakefield perhaps was not happy with these two with their performances at presentation in April 2022 and stating organic growth of £100M within 5 years .

It's clear now why there was an upsurge of buying on Monday and a volume of around 650K on the French side , because news must have been leaked that there was going to be a RNS today , Thursday , and news of CEO appointed. You always wonder why there is a buying / selling frenzy which is unexpected. It's simply because someone has leaked news out . I question is this legal?

I expect director buys will follow from the the new CEO & new executive director .

I believe Mason is an upgrade to Paul Oladimeji , especially with her vast contacts in the molecular industry and knowledge of the genome companies . Mason is very active on LinkedIn, and this suggests to me she is commercially tuned as well .

Secondly , Lyn Rees is confident of winning big contracts . Read his comments below .

Commenting, Lyn Rees, Executive Director and incoming CEO, said: "I am excited to have the opportunity to lead Novacyt in its next stage of development. The molecular diagnostics market is experiencing rapid growth, driven by the continued demand for fast and accurate diagnostics and with our strong portfolio of molecular assays and instruments combined with our leading expertise I believe we are well placed to capture this. I would like to thank James for his support since I joined the Company and look forward to working with the entire team as we continue to deliver our strategy."

I think this is going to court and will not be settled before then . JW believes we will win and is going for the full amount . Hence why PO was replaced by Mason , as he does not need to be actively employed by Novacyt . My opinion .

I believe Novacyt will have £130M+ in June 2024 , which would be plenty for several acquisitions . The reason of appointing LR is for Novacyt to 'grow' and LR is the man with the experience for acquisitions .

Graham Mullis will be key personal at the court case with his account of the whole process with DHSC . Paul Oladimeji would be called up to represent Novacyt for the technical side of things .